Abstract
In the coming years, the drug development process is likely to change dramatically as manufacturers, regulators, and payers across the world face intense pressure to meet the growing needs of their constituents. Higher hurdles in the regulatory and pricing/reimbursement landscape will likely present new challenges to the drug development and market access process, which will in turn impact patient care. Manufacturers of medicines must focus on “intelligent innovation” in which investments are targeted to pursue true therapeutic breakthroughs, to minimize the risk of failure, and to maximize global market access and patient benefit. The future of the medicines landscape must evolve toward a more collaborative framework, where regulatory agencies will pursue a greater degree of convergence and where sponsors, regulators, and payers, as essential stakeholders, will undertake drug development with reimbursement in mind to achieve the common global goal of bringing safe, effective, and affordable medicines to the world’s people.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
US Food and Drug Administration. Pathway to global product safety and quality. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/GlobalProductPathway/default.htm. Accessed October 17, 2012.
EvaluatePharma. World preview 2018: embracing the patent cliff. Available at: http://www.evaluatepharma.com/worldpreview2018.aspx. Accessed October 17, 2012.
US Food and Drug Administration. FDA approves Kalydeco to treat rare form of cystic fibrosis [press release]. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm. Accessed October 17, 2012.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: ethnic factors in the acceptability of foreign clinical data E5(R1). Available at: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/ethnic-factors-in-the-acceptability-of-foreign-clinical-data.html. Accessed October 17, 2012.
Tohkin M. Comparative studies of pharmacokinetics among East Asian populations. Paper presented at: APEC Multi-regional Clinical Trials Tokyo Workshop; November 1, 2011; Tokyo, Japan.
Uyama Y. East-Asian contributions to global drug developments for providing a better drug to patients. Paper presented at: APEC Multi-regional Clinical Trials Tokyo Workshop; November 1, 2011; Tokyo, Japan.
Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and Western countries. Clin Pharmacol Ther. 2010;87:714–720.
European Union. EU statistics and opinion polls. Available at: http://europa.eu/documentation/statistics-polls/index_en.htm. Accessed October 17, 2012.
US Census Bureau. International database. Available at: http://www.census.gov/population/international/data/idb/region.php. Accessed October 17, 2012.
Biotechnology Industry Organization. Clinical trials success rates study. Paper presented at: Biotechnology Industry Organization CEO & Investor Conference; February 15, 2011; New York, New York.
PAREXEL Consulting Analysis. Why NMEs and BLAs Fail in the 1st FDA Review Cycle [unpublished]. Waltham, Massachusetts:PAREXEL; 2012.
PricewaterhouseCoopers. Pharma 2020: virtual R&D. Which path will you take? Available at: http://www.pwc.com/en_GX/gx/pharma-life-sciences/pharma-2020/pharma-2020-supplying-the-future.jhtml. Accessed October 22, 2012.
APEC Life Sciences Innovation Forum Regulatory Harmonization Steering Committee. Vision 2020. A strategic framework: regulatory convergence for medical products by 2020. Paper presented at: 23rd APEC Ministerial Meeting; November 11, 2011; Honolulu, Hawaii.
Jenkins JK. New drug review: 2009 update. Paper presented at: FDA/CMS Summit; December 3, 2009; Washington, DC.
Kitamura M. Bristol-Myers skin-cancer drug Yervoy rejected by U.K. Health Cost Agency. Available at: http://www.bloomberg.com/news/2011-10-13/bristol-myers-s-skin-cancer-drug-rejected-by-u-k-cost-agency.html. Accessed October 17, 2012.
Whalen J. U.K. panel balks at drug payments. Available at: http://online.wsj.com/article/SB10001424052748704810504576305273155198288.html?mod=rss_Health&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+wsj%2Fxml%2Frss%2F3_7089+%28WSJ.com%3A+Health%29. Accessed October 22, 2012.
Eichler HG. How to match the European HTA scientific advice with the regulatory context. Paper presented at: DIA EuroMeeting; March 27, 2012; Copenhagen, Denmark.
Author information
Authors and Affiliations
Corresponding author
Additional information
The contents of this article are based on the Keynote Address, “Achieving Global Market Access for New Medicines in the 21st Century: Collaboration and Convergence,” delivered on May 21, 2012, at the 4th DIA China Annual Meeting in Shanghai, China.
Rights and permissions
About this article
Cite this article
Grignolo, A. Collaboration and Convergence: Bringing New Medicines to Global Markets in the 21st Century. Ther Innov Regul Sci 47, 8–15 (2013). https://doi.org/10.1177/2168479012469951
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479012469951